Table 1.
Patient characteristics.
| Age, sex, and race | Year of ITP diagnosis | Concomitant conditions | Concomitant medications | Time from diagnosis to fostamatinib Tx (years) | No. of previous ITP treatments | Type of previous ITP treatmentsa | Response to previous therapies | Baseline platelets, before fostamatinib (microliter) | |
|---|---|---|---|---|---|---|---|---|---|
| Case 1 | 54, M, Caucasian | 2011 | Hypertension Ascending aorta ectasia |
Sartan derivative | 11 | 2 | Steroids Eltrombopag |
PR Loss of CR |
23,000 |
|
| |||||||||
| Case 2 | 80, F, Caucasian | 2016 | Multinodular goiter Hypertension Hypercholesterolemia Renal lithiasis and gallstone Parkinson's disease |
Levothyroxine Β-adrenergic blocking agents Statins Dopaminergic agents |
6 | 9 | Steroids (PDN and Dexa) IVIG Romiplostim Eltrombopag Splenectomy Rituximab Danazole (+Dexa) IVIG + PDN Anti-CD38 (TAK-079) |
PR PR Brief CR Refractoriness Refractoriness Refractoriness Refractoriness Refractoriness Refractoriness |
6,000 |
M = male, F = female, PDN = prednisone, Dexa = dexamethasone, IVIG = intravenous immunoglobulins, PR = partial response, and CR = complete response. aTreatments are reported in the order prescribed.